Related references
Note: Only part of the references are listed.Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma
Gao-Min Liu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Somatic selection distinguishes oncogenes and tumor suppressor genes
Pramod Chandrashekar et al.
BIOINFORMATICS (2020)
Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice
Satoshi Saida et al.
LEUKEMIA (2020)
Metabolism-associated molecular classification of hepatocellular carcinoma
Chen Yang et al.
MOLECULAR ONCOLOGY (2020)
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Junyu Long et al.
EBIOMEDICINE (2019)
Calcium-activated nucleotidase 1 silencing inhibits proliferation, migration, and invasion in human clear cell renal cell carcinoma
Xin Liu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis
He Li et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Yongcong Yan et al.
HEPATOLOGY INTERNATIONAL (2019)
The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription
Navdeep Malik et al.
NATURE COMMUNICATIONS (2019)
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma (vol 179, pg 561, 2019)
Qiang Gao et al.
CELL (2019)
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Cun Wang et al.
NATURE (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma
Junyu Long et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Human Hepatocellular Carcinomas With a Periportal Phenotype Have the Lowest Potential for Early Recurrence After Curative Resection
Romain Desert et al.
HEPATOLOGY (2017)
Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
Binghua Li et al.
SCIENTIFIC REPORTS (2017)
Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
Li Xu et al.
BRITISH JOURNAL OF CANCER (2017)
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy
Dae Won Kim et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression
Lauren Edwards et al.
MOLECULAR CANCER RESEARCH (2016)
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
Akihiro Fujimoto et al.
NATURE GENETICS (2016)
Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients
Xiajie Wen et al.
ONCOTARGETS AND THERAPY (2016)
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman-Rossi et al.
GASTROENTEROLOGY (2015)
The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
Hongping Xia et al.
ONCOTARGET (2015)
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
Katharina Bluemlein et al.
Oncotarget (2015)
Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality
Livnat Jerby-Arnon et al.
CELL (2014)
Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis
Jiangbo Liu et al.
EUROPEAN JOURNAL OF CANCER (2012)
The Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro
Josefine Gerhardt et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells
Qinwen Wang et al.
CANCER LETTERS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma
Aya Kita et al.
LEUKEMIA RESEARCH (2011)
Association of Core-Binding Factor β With the Malignant Phenotype of Prostate and Ovarian Cancer Cells
J. Nathan Davis et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
Yujin Hoshida et al.
CANCER RESEARCH (2009)
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
Derek Y. Chiang et al.
CANCER RESEARCH (2008)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis
Yuko Takeba et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2007)
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Sandrine Boyault et al.
HEPATOLOGY (2007)
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma:: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level
V Boige et al.
EUROPEAN JOURNAL OF CANCER (2006)
Pyruvate kinase type M2 and its role in tumor growth and spreading
S Mazurek et al.
SEMINARS IN CANCER BIOLOGY (2005)
Share Paper
